Magnurol (Terazosin Hydrochloride)

Terazosin selectively blocks alpha‑1 adrenergic receptors on vascular smooth muscle and prostatic tissue. This blockade prevents norepinephrine‑induced contraction, leading to vasodilation that lowers blood pressure and to relaxation of prostate and bladder neck muscles, which eases urinary flow.

The specific dose of Magnurol is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for terazosin in pregnancy and lactation are limited, and the product is generally not recommended for use in pregnant or nursing women unless the potential benefit outweighs the risk. Clinicians should evaluate each case carefully.

To place an order, submit an enquiry on the Magnurol product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Magnurol (terazosin) belongs to the alpha‑1 blocker class, which differs from ACE inhibitors, ARBs, calcium‑channel blockers, and diuretics. It primarily reduces peripheral resistance and also treats BPH, offering a dual benefit not provided by many other antihypertensives.

Magnurol tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and store out of reach of children.

Magnurol is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should follow the prescriber’s guidance on timing and whether to take it in the morning or evening.

The most serious risks include severe orthostatic hypotension that can cause fainting, priapism (a prolonged erection), and rare cases of liver injury or anaphylaxis. Patients should seek immediate medical attention if they experience sudden dizziness, chest pain, or unusual erections.

Magnurol is contraindicated in patients with known hypersensitivity to terazosin or any component of the formulation, and it should be used with caution in individuals with severe liver disease, recent myocardial infarction, or those already on multiple alpha‑blockers.